相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
Antonios Revythis et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)
BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
Stergios Boussios et al.
CANCERS (2022)
Exosomes and cancer-Diagnostic and prognostic biomarkers and therapeutic vehicle
Xia Wang et al.
ONCOGENESIS (2022)
Applications of Proteomics in Ovarian Cancer: Dawn of a New Era
Aruni Ghose et al.
PROTEOMES (2022)
BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
Sidrah Shah et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer
Liliana Raimundo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
A selective p53 activator and anticancer agent to improve colorectal cancer therapy
Helena Ramos et al.
CELL REPORTS (2021)
Estimated Projection of US Cancer Incidence and Death to 2040
Lola Rahib et al.
JAMA NETWORK OPEN (2021)
First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.
Ryan C. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis
Raffaella Casolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Structural and Drug Targeting Insights on Mutant p53
Ana Sara Gomes et al.
CANCERS (2021)
Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target
Liliana Raimundo et al.
CANCERS (2021)
SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations
Ana Sara Gomes et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2020)
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
Naoise C. Synnott et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
BRCA1/P53: Two strengths in cancer chemoprevention
Liliana Raimundo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta et al.
BRITISH JOURNAL OF CANCER (2020)
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
Eileen M. O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial
Talia Golan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib
Greta Bagnolini et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line
Masaki Kobayashi et al.
Oncotarget (2020)
Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer
Soeren M. Buchholz et al.
CANCERS (2020)
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
PARP inhibitor resistance: the underlying mechanisms and clinical implications
He Li et al.
MOLECULAR CANCER (2020)
PARP inhibition in treatment of pancreatic cancer
Pascal Hammel et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Gain-of-function mutant p53 in cancer progression and therapy
Cen Zhang et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2020)
Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
Bolun Jiang et al.
FRONTIERS IN ONCOLOGY (2020)
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Maddison Rose et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
DNA end resection and its role in DNA replication and DSB repair choice in mammalian cells
Fei Zhao et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer
Christopher J. Halbrook et al.
CELL METABOLISM (2019)
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells
Marinella Roberti et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Tumour lineage shapes BRCA-mediated phenotypes
Philip Jonsson et al.
NATURE (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
Michael Orth et al.
RADIATION ONCOLOGY (2019)
Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions Histopathology, Cytopathology, and Molecular Pathology
Bing Ren et al.
AMERICAN JOURNAL OF PATHOLOGY (2019)
A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection
Chaobin He et al.
FRONTIERS IN ONCOLOGY (2019)
New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma
Sara Gomes et al.
CANCER LETTERS (2019)
Mutant p53 as a guardian of the cancer cell
Fiamma Mantovani et al.
CELL DEATH AND DIFFERENTIATION (2019)
Inhibition of p53 inhibitors: progress, challenges and perspectives
Gema Sanz et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2019)
An update on treatment options for pancreatic adenocarcinoma
Aurelien Lambert et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer
Sofia Palacio et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
BRCA Genes: The Role in Genome Stability, Cancer Sternness and Therapy Resistance
Ielizaveta Gorodetska et al.
JOURNAL OF CANCER (2019)
Phase 1 Trial Evaluating Cisplatin, Gemcitabine, and Veliparib in 2 Patient Cohorts: Germline BRCA Mutation Carriers and Wild-Type BRCA Pancreatic Ductal Adenocarcinoma
Eileen M. O'Reilly et al.
CANCER (2018)
Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
Chunling Hu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R. Hingorani et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Alan Ashworth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
ATR/CHK1 inhibitors and cancer therapy
Zhaojun Qiu et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
Xiangbing Meng et al.
CANCERS (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma
Tim D. D. Somerville et al.
CELL REPORTS (2018)
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer
N. Stojanovic et al.
ONCOGENE (2017)
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
Stephanie A. Yazinski et al.
GENES & DEVELOPMENT (2017)
Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma
Koji Shindo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
Kara N. Maxwell et al.
NATURE COMMUNICATIONS (2017)
Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
Maryam Zanjirband et al.
ONCOTARGET (2017)
Germline mutations in pancreatic cancer and potential new therapeutic options
Rille Pihlak et al.
ONCOTARGET (2017)
Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy
Maya Saison-Ridinger et al.
PLOS ONE (2017)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Andrew J. Aguirre et al.
CANCER CELL (2017)
DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53
S. K. Alam et al.
CELL DEATH AND DIFFERENTIATION (2016)
Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth
M. Aggarwal et al.
CELL DEATH AND DIFFERENTIATION (2016)
Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival
Sonja M. Woermann et al.
GASTROENTEROLOGY (2016)
53BP1 Integrates DNA Repair and p53-Dependent Cell Fate Decisions via Distinct Mechanisms
Raquel Cuella-Martin et al.
MOLECULAR CELL (2016)
Phosphorylated CtIP Functions as a Co-factor of the MRE11-RAD50-NBS1 Endonuclease in DNA End Resection
Roopesh Anand et al.
MOLECULAR CELL (2016)
Replication fork stability confers chemoresistance in BRCA-deficient cells
Arnab Ray Chaudhuri et al.
NATURE (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Distinct binding of BRCA2 BRC repeats to RAD51 generates differential DNA damage sensitivity
Gouri Chatterjee et al.
NUCLEIC ACIDS RESEARCH (2016)
PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
Karolina N. Dziadkowiec et al.
MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY (2016)
A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non-homologous end joining
Sylvie Moureau et al.
OPEN BIOLOGY (2016)
POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).
Talia Golan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
J. Bendell et al.
ANNALS OF ONCOLOGY (2015)
Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis
Masatsugu Hiraki et al.
CHEMISTRY & BIOLOGY (2015)
Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4
Shawna Guillemette et al.
GENES & DEVELOPMENT (2015)
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Spring Holter et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end resection
Vera Boersma et al.
NATURE (2015)
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Guotai Xu et al.
NATURE (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
ATM and ATR as therapeutic targets in cancer
Anika Maria Weber et al.
PHARMACOLOGY & THERAPEUTICS (2015)
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma
Sameer A. Dhayat et al.
PLOS ONE (2015)
The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
Helen Cavanagh et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2015)
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
T. Golan et al.
BRITISH JOURNAL OF CANCER (2014)
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Patricia A. J. Muller et al.
CANCER CELL (2014)
CBP-93872 Inhibits NBS1-Mediated ATR Activation, Abrogating Maintenance of the DNA Double-Strand Break-Specific G2 Checkpoint
Takahisa Hirokawa et al.
CANCER RESEARCH (2014)
Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53
Ivanildce Cristiane Ireno et al.
CARCINOGENESIS (2014)
Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Susann Weissmueller et al.
CELL (2014)
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Peter Bouwman et al.
CLINICAL CANCER RESEARCH (2014)
DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities
Atsushi Shibata et al.
MOLECULAR CELL (2014)
Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity
J. Xu et al.
CELL DEATH & DISEASE (2014)
Unravelling mechanisms of p53-mediated tumour suppression
Kathryn T. Bieging et al.
NATURE REVIEWS CANCER (2014)
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
R. Alvarez et al.
BRITISH JOURNAL OF CANCER (2013)
Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death
Laura Conradt et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
Sophie Gourgou-Bourgade et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Advanced-stage pancreatic cancer: therapy options
Jens Werner et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer
Zsofia K. Stadler et al.
CANCER (2012)
Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia
Mitsuro Kanda et al.
GASTROENTEROLOGY (2012)
Mutant p53: one name, many proteins
William A. Freed-Pastor et al.
GENES & DEVELOPMENT (2012)
Genetic susceptibility to pancreatic cancer
Alison P. Klein
MOLECULAR CARCINOGENESIS (2012)
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
E. Fokas et al.
CELL DEATH & DISEASE (2012)
An Mdm2 antagonist, Nutlin-3a, induces p53-dependent and proteasome-mediated poly(ADP-ribose) polymerase1 degradation in mouse fibroblasts
Shingo Matsushima et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage
Juhong Jiang et al.
CANCER RESEARCH (2011)
Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53
Paul Timpson et al.
CANCER RESEARCH (2011)
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
D. Li et al.
CELL DEATH AND DIFFERENTIATION (2011)
MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
N. V. Rajeshkumar et al.
CLINICAL CANCER RESEARCH (2011)
p53 null Fluorescent Yellow Direct Repeat (FYDR) mice have normal levels of homologous recombination
Dominika M. Wiktor-Brown et al.
DNA REPAIR (2011)
Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
J. H. M. Schellens et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Elevated Transcript Levels From the MDM2 P1 Promoter and Low p53 Transcript Levels Are Associated With Poor Prognosis in Human Pancreatic Ductal Adenocarcinoma
Lukasz Filip Grochola et al.
PANCREAS (2011)
Rad52 inactivation is synthetically lethal with BRCA2 deficiency
Zhihui Feng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
DNA Damage-Induced Cytotoxicity Is Dissociated from BRCA1's DNA Repair Function but Is Dependent on Its Cytosolic Accumulation
Hong Wang et al.
CANCER RESEARCH (2010)
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Samuel F. Bunting et al.
CELL (2010)
MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function
Asfar S. Azmi et al.
EUROPEAN JOURNAL OF CANCER (2010)
BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications
Rebecca J. Linger et al.
FEBS JOURNAL (2010)
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33
Gloria M. Petersen et al.
NATURE GENETICS (2010)
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
Peter Bouwman et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
Abrogation of the G(2) Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents
Suzanne Leijen et al.
CURRENT CLINICAL PHARMACOLOGY (2010)
PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response
Feng Zhang et al.
CURRENT BIOLOGY (2009)
PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2
Fan Zhang et al.
MOLECULAR CANCER RESEARCH (2009)
Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells
X. Sui et al.
ONCOGENE (2009)
PALB2 is an integral component of the BRCA complex required for homologous recombination repair
Shirley M. H. Sy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Mechanism of eukaryotic homologous recombination
Joseph San Filippo et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance
Weixin Wang et al.
CANCER BIOLOGY & THERAPY (2008)
Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer Cells
Liping Li et al.
CANCER RESEARCH (2008)
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
Elizabeth M. Swisher et al.
CANCER RESEARCH (2008)
DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells
Zhiyong Mao et al.
CELL CYCLE (2008)
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis
L. Weinmann et al.
CELL DEATH AND DIFFERENTIATION (2008)
Homologous recombination in DNA repair and DNA damage tolerance
Xuan Li et al.
CELL RESEARCH (2008)
Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells
Muraildhar L. Hegde et al.
CELL RESEARCH (2008)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway
J. E. Kravchenko et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
P53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
Hoseok Song et al.
NATURE CELL BIOLOGY (2007)
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
K. Gudmundsdottir et al.
ONCOGENE (2006)
BRCA1 DNA-binding activity is stimulated by BARD1
AM Simons et al.
CANCER RESEARCH (2006)
P53 modulates homologous recombination by transcriptional regulation of the RAD51 gene
C Arias-Lopez et al.
EMBO REPORTS (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction
HJ Yang et al.
NATURE (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation
JM Stommel et al.
EMBO JOURNAL (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
The interaction of p53 with replication protein A mediates suppression of homologous recombination
LY Romanova et al.
ONCOGENE (2004)
DNA damage induces p53-dependent BRCA1 nuclear export
ZH Feng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors
N Issaeva et al.
NATURE MEDICINE (2004)
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray
A Maitra et al.
MODERN PATHOLOGY (2003)
Insights into DNA recombination from the structure of a RAD51-BRCA2 complex
L Pellegrini et al.
NATURE (2002)
Therapeutic Exploitation of Checkpoint Defects in Cancer Cells Lacking p53 Function
Helen Dixon et al.
CELL CYCLE (2002)
The processing of Holliday junctions by BLM and WRN helicases is regulated by p53
Q Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Autoubiquitination of the BRCA1-BARD1 RING ubiquitin ligase
A Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets
TK MacLachlan et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
VJN Bykov et al.
NATURE MEDICINE (2002)
The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation
R Hashizume et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain
C Gaiddon et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Repression of BRCA1 through a feedback loop involving p53
TK MacLachlan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Tumor suppressor p53 is required to modulate BRCA1 expression
P Arizti et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma
H Maacke et al.
ONCOGENE (2000)
分享论文
